0

Month: February 2016

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

Results of a recent analysis that compared the efficacy, safety, and metabolic effects of the angiotensin-receptor blocker (ARB) azilsartan medoxomil to valsartan and olmesartan separately in patients with prediabetes and type 2 diabetes found that azilsartan (80 mg) lowered systolic blood pressure to a significantly greater degree than either valsartan or olmesartan. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

FH Foundation Initiative Helps “FIND FH”

Officially launched in January 2014 by the FH Foundation, FIND FH® is a specific data mining initiative that uses multiple types of healthcare datasets to identify probable individuals with familial hypercholesterolemia, or FH, and provides a resource for healthcare professionals to encourage screening.

The initiative consists of three elements, the first of which is a lab and claims algorithm based on a database that the FH Foundation developed of more than 89 million Americans with cardiovascular disease. An EHR (electronic health records) algorithm and HCP/individual engagement comprise the second and third elements of the FIND FH® initiative, respectively. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn